FIELD: chemistry.
SUBSTANCE: stability is achieved by crystallising drotaverine hydrochloride in the presence of a stabilising additive of a mixture of citric acid and its sodium salt in amount of up to 1.0% of the weight of drotaverine hydrochloride fed for crystallisation. In order to protect drotaverine hydrochloride from oxidative decomposition, the composition of the solution before crystallising the end product may include additional stabilising components: trilon B, sodium metabisulphite, benzethonium chloride in amount of not more than 1.0% of the weight of drotaverine hydrochloride fed for crystallisation.
EFFECT: high stability during prolonged storage.
2 cl, 2 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-STABLE PHARMACEUTICAL FORMULATION OF LYOPHILISATE OF 3-OXYPYRIDINE AND METHYLPYRIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | 2012 |
|
RU2504376C1 |
| INJECTION SOLUTION WITH EXPRESSED ANALGESIC EFFECT AND METHOD FOR ITS PREPARING | 2004 |
|
RU2254852C1 |
| RECTAL SUPPOSITORY MEDICINAL PRODUCT AND METHOD FOR ITS PREPARATION | 2018 |
|
RU2689320C1 |
| RECTAL SUPPOSITORIES AND METHOD FOR PREPARATION THEREOF (OPTIONS) | 2017 |
|
RU2674029C1 |
| PHARMACEUTICAL COMPOSITION FOR PARENTERAL INTRODUCTION AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2635759C1 |
| REMEDY FOR TREATING DISEASES OF JOINTS | 2005 |
|
RU2275190C1 |
| METHOD FOR PREPARING BENZYLPENICILLIN DIETHYLAMINOETHYL ESTER HYDROIODIDE | 2006 |
|
RU2305100C1 |
| INJECTION DOSAGE FORM FOR TREATING ACUTE ISCHEMIC STROKE AND CRANIOCEREBERAL INJURY, METHOD FOR PREPARING AND USING | 2009 |
|
RU2431496C2 |
| STABILISED COMPOSITION CONTAINING AT LEAST ONE ADRENERGIC COMPOUND | 2010 |
|
RU2527680C2 |
| AGENT FOR TREATMENT OF JOINT DISEASES | 2005 |
|
RU2275199C1 |
